Bioniz - Spotlight

Spotlight

Bioniz Therapeutics to Present New Data at the 2017 ASH Annual Meeting

— First Data from BNZ-1 Phase 1 trial to be Highlighted in Oral Presentation–

Irvine, CA, November 2, 2017 — Bioniz Therapeutics, Inc., a clinical stage biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and T-cell malignancies, today announced that new data from the company’s lead BNZ-1 program will be presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, December 9-12, 2017. BNZ-1 is a novel PEGylated peptide that inhibits cytokines IL-2/IL-9/L-15.

In total, two abstracts led by Bioniz and its collaborators at the University of Virginia (UVA) Cancer Center and the National Cancer Institute (NCI) describing new clinical and experimental data from the company’s BNZ-1 program have been accepted for oral and poster presentations at ASH.

The accepted abstracts are listed below and are now available online on the ASH conference website: https://ash.confex.com/ash/2017/webprogram/start.html#srch=words%7CBNZ-1%7Cmethod%7Cand%7Cpge%7C1%7CbyDayany%7Cany%7CbySymposiumany%7Cany

Dr. Paul Frohna, Senior Vice President of Clinical Development of Bioniz Therapeutics, will be giving an oral Presentation entitled:

Results from a First-in-Human Study with BNZ-1: A Novel Peptide Inhibitor of IL-2, IL-9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8+ Central Memory T-Cells

  • Date & Time: Monday, December 11, 2017: 3:45 PM
  • Session Title: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: T cell biology and therapies
  • Abstract Number: 695
  • Location: Building C, Level 1, C108-C109

Tracy Wang (UVA) will present a poster entitled:
Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia, which describes the ex vivo effects of BNZ-1 on patient-derived LGL and ATL cells.

  • Date & Time: Monday, December 11, 2017, 6:00 PM-8:00 PM
  • Session Title: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III
  • Abstract Number: 3585
  • Location: Building A, Level 1, Hall A2

About BNZ-1

Bioniz’s lead development candidate, BNZ-1, is a PEGylated peptide that functions as a selective and simultaneous inhibitor of cytokines IL-2, IL-9, and IL-15. The company currently plans to develop BNZ-1 for the treatment of the T-cell malignancies LGL and CTCL, as well as for the autoimmune disease Alopecia Areata. BNZ-1 is currently being evaluated in a Phase 1b Multiple Ascending Dose study in Healthy Volunteers (NCT03239379).

About Bioniz

Bioniz is a clinical-stage biopharmaceutical company leading the discovery and development of first-in-class multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer. Bioniz leverages its world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health (NIH), to develop a novel approach to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact. Bioniz’ innovative platform has resulted in multiple peer-reviewed publications in notable scientific journals. Bioniz’ lead product candidate, BNZ-1, has completed a Phase 1 clinical trial in healthy volunteers. For more information, please visit www.bioniz.com.
_______________________

CONTACT:

David Eichhorn
Director of Operations
949-273-6000 ext 600
David.Eichhorn@bioniz.com